2015PubMedRequires access

[Effects of resveratrol on hippocampal astrocytes and expression of TNF-α in Alzheimer's disease model rate].

Xuejiao Cheng, Qian Wang, Na Li, Haifeng Zhao

Open publisher page 15 citations

Abstract

OBJECTIVE: To explore the effects of resveratrol on astrocyte and TNF-α in hippocampus of Alzheimer's disease (AD) model rats. METHODS: Sixty rats were randomly divided into six groups: sham control group, model group, resveratrol 20, 40, 80 mg/kg group, and estradiol valerate group (0.8 mg/kg). The model of AD was established by ovariectomy combined injection of D-galactose (100 mg/kg). Twelve weeks later, the heart perfusion in vivo was done and then the hippocampus was fixed. Additionally, the changes of hippocampal astrocytes and TNF-α expression were detected by immunohistochemistry. RESULTS: The levels of glial fibrillary acidic protein (GFAP) and TNF-α in the model group were significantly higher than those of the sham control group (P < 0.01). No marked difference in the production of GFAP was observed between the resveratrol 20 mg/kg group and the model group (P > 0.05). However, the resveratrol 40, 80 mg/kg and estradiol valerate treated groups showed a decrease in the expression of GFAP compared with the model group (P < 0.01). Moreover, with the increasing of resveratrol concentration, the expression of GFAP decreased gradually. The levels of TNF-α decreased markedly in Res 20, 40, 80 mg/kg and estradiol valerate group compared with the model group (P < 0.01). CONCLUSION: These results suggest that the activation of astrocytes and the secretion of TNF-α can be inhibited by Res in AD rats.

About this research paper

What this paper is about

OBJECTIVE: To explore the effects of resveratrol on astrocyte and TNF-α in hippocampus of Alzheimer's disease (AD) model rats. METHODS: Sixty rats were randomly divided into six groups: sham control group, model group, resveratrol 20, 40, 80 mg/kg group, and estradiol valerate group (0.8 mg/kg). The model of AD was established by ovariectomy combined injection of D-galactose (100 mg/kg). Twelve weeks later, the heart perfusion in vivo was done and then the hippocampus was fixed. Additionally, the changes of hippocampal astrocytes and TNF-α expression were detected by immunohistochemistry. RESULTS: The levels of glial fibrillary acidic protein (GFAP) and TNF-α in the model group were significantly higher than those of the sham control group (P < 0.01). No marked difference in the production of GFAP was observed between the resveratrol 20 mg/kg group and the model group (P > 0.05). However, the resveratrol 40, 80 mg/kg and estradiol valerate treated groups showed a decrease in the expression of GFAP compared with the model group (P < 0.01). Moreover, with the increasing of resveratrol concentration, the expression of GFAP decreased gradually. The levels of TNF-α decreased markedly in Res 20, 40, 80 mg/kg and estradiol valerate group compared with the model group (P < 0.01). CONCLUSION: These results suggest that the activation of astrocytes and the secretion of TNF-α can be inhibited by Res in AD rats.

Why it matters

OpenAlex reports 15 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

OBJECTIVE: To explore the effects of resveratrol on astrocyte and TNF-α in hippocampus of Alzheimer's disease (AD) model rats. METHODS: Sixty rats were randomly divided into six groups: sham control group, model group, resveratrol 20, 40, 80 mg/kg group, and estradiol valerate group (0.8 mg/kg). The model of AD was established by ovariectomy combined injection of D-galactose (100 mg/kg). Twelve weeks later, the heart perfusion in vivo was done and then the hippocampus was fixed. Additionally, the changes of hippocampal astrocytes and TNF-α expression were detected by immunohistochemistry. RESULTS: The levels of glial fibrillary acidic protein (GFAP) and TNF-α in the model group were significantly higher than those of the sham control group (P < 0.01). No marked difference in the production of GFAP was observed between the resveratrol 20 mg/kg group and the model group (P > 0.05). However, the resveratrol 40, 80 mg/kg and estradiol valerate treated groups showed a decrease in the expression of GFAP compared with the model group (P < 0.01). Moreover, with the increasing of resveratrol concentration, the expression of GFAP decreased gradually. The levels of TNF-α decreased markedly in Res 20, 40, 80 mg/kg and estradiol valerate group compared with the model group (P < 0.01). CONCLUSION: These results suggest that the activation of astrocytes and the secretion of TNF-α can be inhibited by Res in AD rats.

Key concepts: Glial fibrillary acidic protein, Resveratrol, Estradiol valerate, Endocrinology, Hippocampal formation, Astrocyte, Internal medicine, Hippocampus

Related papers

Back to paper searchBrowse research topicsOriginal source
[Effects of resveratrol on hippocampal astrocytes and expression of TNF-α in Alzheimer's disease model rate]. — Research Paper | ScholarLens